Nabriva Therapeutics PLC expected to post a loss of 19  cents a share - Earnings Preview

Nabriva Therapeutics

25/03/2022 21:32

* Nabriva Therapeutics PLC  NBRV.OQ   NBRV.O  is expected
to show
a rise in quarterly revenue when it reports  results on March
29. 
    * The Dublin Ireland; Republic of-based   company is
expected to
report  a 310.5% increase in revenue to $10.099 million from
$2.46 million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Nabriva
Therapeutics PLC
is for a loss of 19 cents per share. For the same quarter last
year, the company reported a loss of $1.11 per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Nabriva
Therapeutics PLC is $2.68​, above​ its last closing price
of $0.47. ​​​

This summary was machine generated March 25 at 21:32 GMT.  All
figures in US dollars  unless otherwise stated